Fosamax Lawsuit Loans

Have a Settled Fosamax Lawsuit But Need Cash Now?

TriMark Legal Funding provides post-settlement funding on settled Fosamax lawsuits nationwide.

Legal Funding on Fosamax Lawsuits

TriMark Legal Funding is one of America’s leading personal injury accident loan companies. We provide pre-settlement funding and post-settlement funding (lawsuit loans) to injured plaintiffs nationwide while they wait for their lawsuit settlements.

At TriMark Legal Funding, we offer non-recourse lawsuit funding cash advances to plaintiffs who are involved in either pending or settled legal claims, often in 24 hours or less.

Lawsuit loans are a discreet, sensible way to keep your head above water until your attorney has finished negotiating your lawsuit settlement.

Let’s Talk!

Call us at (877) 932-2628 or send us your details & we’ll call you.

    Have Questions?
    Call and speak with one of our funding experts today.

    Important Notice About Fosamax Lawsuit Funding

    TriMark Legal Funding only offers post-settlement funding on settled Fosamax lawsuits at this time

    This means that to qualify for funding consideration, you must have already signed your settlement agreement and know either

    1. The gross amount of your settlement OR
    2. The actual net amount you will be receiving after all deductions (attorney fees, case costs, medical liens, etc.)

    If you have a settled Fosamax lawsuit and would like to apply for settlement funding, please apply here.

    How Lawsuit Loans Work

    TriMark Legal Funding specializes in helping personal injury accident victims.
    Our non-recourse legal funding is a simple 3-step process:

    1. Apply for Funding

    You can either apply online or call us toll-free at (877) 932-2628. We’ll answer all of your questions and gather some basic facts about your case.

    2. Review & Approval

    Our team will work directly with your attorney to review your case. Approvals can happen as quickly as 1 hour after receipt of all required information.

    3. Receive Cash

    A funding agreement is sent via DocuSign. After signed copies are returned, your cash is sent to you by wire transfer or FedEx Overnight.

    Fosamax Lawsuit Funding

    If you have filed a lawsuit against Merck & Company because of a femur fracture, jaw surgery, or jaw replacement, and are interested in a settlement loan against your case, we can help.

    TLF offers post-settlement loans to plaintiffs who have already signed their claim release.

    What is Fosamax?

    Fosamax (Alendronate) is prescribed to men and women for the prevention or treatment of osteoporosis and other bone diseases. Fosamax is manufactured by Merck & Company and received FDA approval in 1995. Since 2008, generic versions of this drug, called Alendronate, manufactured by Barr Pharmaceuticals and Teva Pharmaceuticals, have been available on the market.

    The idea behind the drug is that it should reduce the risk of broken bones and fractures in patients. Unfortunately, and herein lies the problem, it is known for occasionally causing the opposite effect: It is known to cause serious femur fractures, along with other broken bones. Additionally, it has been reported that Fosamax might cause other serious medical conditions such as osteromyeltitis, which is the inflammation of bone marrow, and dead jaw disease (osteonecrosis).

    Over the last several years, thousands of people have filed lawsuits when health complications emerged after they began taking the drug.

    Medical experts have amassed overwhelming evidence that links the drug to thigh bone fractures resulting from little to no force being exerted to the bone.

    The FDA encouraged Merck to add label warnings about bone fractures, but it took Merck over a year to include fractures as one of the possible side effects.

    The active ingredient is Alendronic Acid. The medicine is considered a success and is, in fact, still available for sale and many post-menopausal women who used the drug have experienced improvement with regards to osteoporosis.

    Side effects are very serious and those injured by them can claim just compensation.

    While Fosamax is supposed to strengthen the bone mass in women and men, it has been documented that the drug may cause different bone fractures and femur fractures. We have included a shortlist of other side effects of the drug Fosamax.

    Fosamax Side Effects

    These are some of the known side effects that have been reported and confirmed:

    • Chest pain
    • Chronic back pain
    • Severe bone pain
    • Coughing up blood
    • Eye problems
    • Pain when swallowing
    • Flu-like symptoms
    • Hip and thigh pain
    • Joint and muscle pain
    • Nausea, diarrhea or constipation
    • Dizziness
    • Pain in the Upper Stomach
    • Pain under the ribs
    • Jaw Pain
    • Severe heartburn
    • Swelling of the face, lips, tongue, throat and hands


    • Abilify
    • Accutane
    • Actonel
    • Actos
    • Androgel
    • Avandia
    • Avelox
    • Baycol
    • Belviq
    • Bextra
    • Boniva
    • Celebrex
    • Cipro
    • Coumadin
    • Crestor
    • Darvocet
    • Darvon
    • Dexatrim
    • Dexilant
    • Eliquis
    • Ephedrine
    • Fen-Phen
    • Fluoroquinolones
    • Fosamax
    • Gadolinium Dye
    • GranuFlo & NaturaLyte
    • Heparin
    • Invokana
    • Levaquin
    • Lipitor
    • Lipobay
    • Losartan
    • Meridia
    • Nexium
    • Paxil
    • Pergolide
    • Permax
    • Plavix
    • Prempro
    • Prevacid
    • Prexige
    • Prilosec
    • Propulsid
    • Proton Pump Inhibitors (PPI)
    • Protonix
    • Prozac
    • Raptiva
    • Ranitidine
    • Reglan
    • Rezulin
    • RotaShield
    • Seldane
    • Seroquel
    • Taxotere
    • Testosterone
    • Topomax
    • Trasylol
    • Trovan
    • Truvada
    • Valsartan
    • Vioxx
    • Warfarin
    • Yasmin
    • Yaz
    • Zantac
    • Zelnorm
    • Zocor
    • Zofran
    • Zoloft
    • Zyban
    • Zyprexa

    Medical Devices

    • Bair Hugger
    • ERCP Scope
    • Guidant Heart Device
    • IUD Litigation
      • Mirena IUD
      • Paragard IUD
    • Kugel Mesh Patch
    • Medtronic
      • Infuse Bone Graft
      • Marquis Defibrillator
      • Sprint Fidelis
    • NuvaRing
    • Ortho Evra Patch
    • Phillips CPAP
    • Power Morcellator
    • Surgical Robot
      • Da Vinci Robot

    Products / Other

    • 9/11 First Responder Settlements
    • Big Tobacco
    • Class Action Lawsuits
    • Commercial Litigation Funding
    • Deepwater Horizon MDL 2179
    • Dow Corning Breast Implant
    • DuPont C-8 (Teflon) MDL 2433
    • E-Cigarettes
      • JUUL
    • FIU Bridge Collapse
    • Hertz False Arrest Lawsuit
    • Iraq War Hostages
    • Paraquat Weedkiller
    • PG&E Wildfire Lawsuits
    • Sports Injury Lawsuits
      • NCAA Concussion
      • NFL Concussion
      • WWE Concussion
    • Takata Airbag Settlement

    Apply For Fosamax Lawsuit Settled Case Funding

    Lawsuit Funding FAQ Apply Now

    To qualify for an Accutane lawsuit cash advance, you must have a settled Fosamax lawsuit. Pending lawsuits are not eligible at this time.

    To qualify, you must have an already signed Fosamax settlement agreement which clearly shows either the gross amount of your settlement or the actual net amount you will be receiving after all deductions (attorney fees, case costs, medical liens, medical hold-backs, etc.) have been made.

    If you have a settled Fosamax lawsuit and need funding, either:

    Call Us At (877) 932-2628 or

    Latest Developments in the Fosamax Lawsuit…

    On remand from the U.S. Supreme Court, the U.S. Court of Appeals for the Third Circuit has in turn remanded the case to the district court to determine whether state law claims are preempted by federal law in the 500+ lawsuits pending regarding the medication Fosamax in Merck Sharpe & Dohme v. Albrecht. As previously discussed on this blog in May 2019, the United States Supreme Court held that the issue of federal preemption is one to be decided by the court and not a jury, while somewhat clarifying the “clear evidence” standard governing the analysis. After the high court’s decision, it was unclear whether the Third Circuit would remand the cases to the district court for application of the Supreme Court’s guidance or decide the issue – a legal one, after all, as just declared by the Supreme Court – itself de novo. Following supplemental briefing by the parties,… Read more
    After years of limited guidance, the Supreme Court has finally provided direction to lower courts on the issue of preemption when they delivered their opinion in Merck v. Albrecht. “Preemption” is a common defense used by defendants in pharmaceutical mass tort litigation. Through this defense, pharmaceutical companies argue that the state law causes of action are preempted by the Food and Drug Administration’s (FDA) control over drug and medical device approval and labeling. The Preemption Defense The Merck v. Albrecht case centers the drug, Fosamax, as a focal point in the mass tort litigation. Fosamax is pharmaceutical used for osteoporosis treatment and the case revolves around atypical femur fractures caused by use of the osteoporosis drug. Merck, the maker of Fosamax, asserted the preemption defense. Merck argued that it was the state’s failure to warn consumers of the drug’s risk and causes of action could not be brought against Merck… Read more
    The US Supreme Court vacated and remanded a products liability case involving claims alleging a failure to warn about risks of stress fractures related to the use of Fosamax, which is manufactured by Merck Sharpe & Dohme Corp. (“Merck”). Fosamax is a drug that treats and prevents osteoporosis in post-menopausal women. Merck argued that the claims should be dismissed as they submitted “clear evidence” that FDA regulations prohibited them from changing the Fosamax label to include the stress fracture risk warnings. The Supreme Court held that the Third Circuit incorrectly determined that “clear evidence” is a question of fact for a jury; rather, the Court held that “clear evidence” is a question of law as it involves a legal determination about an agency decision. The FDA approved the sale of Fosamax in 1995. At that time, the Fosamax label did not warn of the risk of atypical femoral fracture, a type of… Read more
    The U.S. Supreme Court on Monday handed a victory to Merck & Co – at least for now – by throwing out a lower court ruling that had revived hundreds of lawsuits accusing the company of failing to properly warn patients of debilitating thigh-bone fractures from taking its osteoporosis drug Fosamax. The nine justices unanimously directed the Philadelphia-based 3rd U.S. Circuit Court of Appeals to reconsider its decision allowing the lawsuits to proceed even though federal regulators had rebuffed Merck when the company sought to add a warning to Fosamax’s label about the fracture risk. The decision added clarity to a defense used by drug makers against product liability claims in which they argue that such litigation is preempted under federal law and the U.S. Constitution when a federal agency takes certain actions, as the Food and Drug Administration did in this case. In a decision written by Justice Stephen… Read more
    The fate of about 500 lawsuits involving the drug Fosamax is now in the hands of the U.S. Supreme Court. The nation’s highest court has agreed to consider overturning an appellate court ruling that reinstated the lawsuits after a federal trial judge dismissed them. The issue involves whether Merck, the manufacturer of the osteoporosis drug, failed to warn of the danger that patients taking Fosamax could develop a specific type of thigh bone fractures. Merck argues that it asked the U.S. Food and Drug Administration to approve such a warning on its label, but the FDA denied its request. Lawyers for the injured patients say Merck asked for a warning about a different kind of fracture than those involved in the lawsuits. The Third Circuit Court of Appeals ruled in March 2017 that jurors should decide the issue. But the Trump administration — invited by the Supreme Court to weigh in — maintained this… Read more
    Merck & Co. has another chance for a reprieve in its long-running fight against Fosamax liability lawsuits. After an appeals court revived hundreds of patient claims last year, the U.S. Supreme Court has decided to hear Merck’s bid to put them to rest again. Merck argues that the FDA rebuffed its 2008 bid to update the osteoporosis drug's label to warn of a link to severe bone fractures, but decided to order a warning in October 2010, when Merck did so. Now, Merck shouldn’t be held liable for that lack of a warning, because the FDA’s labeling power shields it, the company says. And the high court will now review that argument, in an important development for the drug industry. The question of FDA pre-emption has made its way through multiple courts in recent years, and Merck’s Supreme Court appeal could settle it. That, in turn, could affect product liability cases… Read more
    Merck & Co Inc is urging a U.S. appeals court to reconsider a ruling that revived hundreds of lawsuits accusing the company of failing to adequately warn about the risks of thigh bone fractures associated with its osteoporosis drug Fosamax. In papers filed on Wednesday, Merck asked the 3rd U.S. Circuit Court of Appeals in Philadelphia to grant a rehearing by the three-judge panel that issued the March 22 ruling or for a rehearing by the full 14-judge court…. Read more
    A federal appeals court on Wednesday revived claims by several hundred plaintiffs who accused Merck & Co of failing to adequately warn about the risks of thigh bone fractures associated with its osteoporosis drug Fosamax. In a 3-0 decision, the 3rd U.S. Circuit Court of Appeals in Philadelphia said the plaintiffs may proceed to trial on their failure-to-warn claims, and a lower court judge erred in finding the claims pre-empted by federal law. Merck said it is reviewing its options, and that a judge, not a jury, should decide the pre-emption question. It also said it remains “confident” in Fosamax’s safety and effectiveness. David Frederick, a lawyer for the plaintiffs, did not immediately respond to requests for comment. Fosamax, whose chemical name is alendronate sodium, has been prescribed to treat or prevent bone loss in post-menopausal women since 1995. But the plaintiffs claimed to suffer atypical femur fractures from long-term… Read more
    Merck & Co Inc said on Monday that it was prepared to pay $27.7 million to settle lawsuits by hundreds of people who sued the company over allegations that its osteoporosis drug Fosamax caused bones in the jaw to deteriorate. Lawyers for Merck and plaintiffs disclosed the proposed settlement at a court hearing in New York to resolve 1,140 lawsuits pending in federal and state courts. Any settlement would need to be approved by a judge. Merck, which confirmed the agreement later on Monday, said the accord requires a 100 percent participation rate and evidence that the claimants satisfy eligibility requirements. The deal covers about 1,200 people, the company said. “We hope to bring this to a successful conclusion,” Paul Strain, a lawyer for Merck, said at the hearing in U.S. District Court in Manhattan before Judge John Keenan, who has presided over federal litigation by plaintiffs claiming that they… Read more
    Doctors prescribe Fosamax to prevent age-related bone damage. The drug can cause minor side effects including abdominal pain, acid regurgitation and constipation. In rare cases, people who take the drug may suffer from serious side effects such as femur fractures, jaw problems and esophageal ulcers. For many people, one of the worries that comes with getting older is the risk of developing osteoporosis. This debilitating disease makes bones so brittle they easily break. When Fosamax (alendronate) was introduced in 1995, it was promoted as the solution to osteoporosis and other bone-damaging diseases. However, studies show that the drug causes serious side effects that may be more problematic than osteoporosis itself. The drug’s manufacturer, Merck, says the most common side effects include gastrointestinal issues, such as nausea, diarrhea, constipation and cramping. The U.S. Food and Drug Administration documented several of the drug’s more serious side effects and subsequently distributed numerous warnings. Though rare,… Read more
    Kent Klaudt of the national plaintiffs’ law firm Lieff Cabraser Heimann & Bernstein, LLP announced that Reba Inez Patton and her husband Patrick Patton of Tennessee have filed a lawsuit in the Superior Court of New Jersey against Merck & Co., the manufacturer of Fosamax, and GlaxoSmithKline, LLC, the manufacturer of Boniva, alleging these prescription drugs, which fall within the category of drugs known as bisphosphonates, increase the risk of atypical bone fractures and caused Mrs. Patton severe and permanent injuries. Mrs. Patton was prescribed both Fosamax and Boniva. Mrs. Patton used Fosamax from approximately 2001 to 2006, and Boniva from approximately 2006 to 2010. On December 10, 2010, Mrs. Patton suffered a low energy, atypical femoral fracture when she took a step to walk up a flight of stairs. "I wish this never happened to me. When I walk, it is scary because I do not want to fall… Read more
    Long-term users of the bone-strengthening drugs Fosamax, Actonel, Boniva and other oral bisphosphonates may face a doubled risk of throat cancer, according to the results of a new study.  The study is published in the latest issue of the British Medical Journal (BMJ), and it appears to contradict a similar study published last month that found no link between oesophageal cancer and oral biphosphonates like Fosamax. Researchers from Oxford University looked at the UK General Practice Research Database and found that those subjects who filled 10 or more prescriptions for oral biphosphonates had nearly twice the chance of contracting throat cancer than those who were not taking the drugs. Researchers said that risk did not change regardless of age, sex, smoking, alcohol use, weight or the use of a variety of other drugs. … Read more

    See More